MedTrace Logo

Empagliflozin vs Metformin in PCOS

NCT03008551 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-07-15

No results posted yet for this study

Summary

This a randomised open-label parallel study involving women with polycystic ovary syndrome (PCOS). The patients will be randomised either to metformin 1500mg or empagliflozin 25mg daily for three months. The aim of the study is to examine the effect of empagliflozin on hormonal, metabolic and cardiovascular risk markers and quality of life in women with PCOS.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Empagliflozin

Each participant will receive empagliflozin 25mg daily for 3 months.

DRUG

Metformin

Each participant will receive metformin 1500mg daily for 3 months.

Sponsors & Collaborators

  • Hull University Teaching Hospitals NHS Trust

    lead OTHER_GOV

Principal Investigators

  • Thozhukat Sathyapalan, MBBS FRCP MD · University of Hull/Hull and East Yorkshire Hospitals NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-18
Primary Completion
2018-04-02
Completion
2018-04-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03008551 on ClinicalTrials.gov